Selective progesterone receptor modulators 2: Use in reproductive medicine

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 14, 2008, Pages 2473-2485

  Benagiano, Giuseppe ^a   Bastianelli, Carlo ^a   Farris, Manuela ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiprogestins; Contraception; Emergency contraception; Endometriosis; In vitro fertilisation; Selective progesterone receptor modulators; Uterine leiomyomata

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; ANTIGESTAGEN; ASOPRISNIL; CHORIONIC GONADOTROPIN; CONTRACEPTIVE AGENT; DANAZOL; DESOGESTREL; EPIDERMAL GROWTH FACTOR; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GONADORELIN; GONADORELIN AGONIST; LEUPRORELIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ONAPRISTONE; ORAL CONTRACEPTIVE AGENT; ORG 33628; PLACEBO; PROGESTERONE RECEPTOR MODULATOR; ULIPRISNIL ACETATE; UNCLASSIFIED DRUG;

AMENORRHEA; ANOVULATION; BLEEDING DISORDER; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTRACEPTION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EMERGENCY CONTRACEPTION; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HORMONAL ABORTION; HORMONAL REGULATION; HUMAN; LEIOMYOMA; LONG TERM CARE; LOW DRUG DOSE; LUTEAL PHASE; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION; NAUSEA; NONHUMAN; OVULATION INHIBITION; PATHOGENESIS; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; REPRODUCTION; REVIEW; SINGLE DRUG DOSE; UNWANTED PREGNANCY; UTERUS MYOMA; VOMITING;

CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; FERTILITY; HUMANS; RECEPTORS, PROGESTERONE; REPRODUCTIVE MEDICINE;

EID: 54349089393     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.14.2473     Document Type: Review

References (109)

1. Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 1: use during pregnancy. Expert Opin Pharmacother 2008;9(14):2459-72
2. Elger W, Bartley J, Schneider B, et al. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-23
3. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307
4. Kloostenboer HJ, Deckers GH, De Gooyer ME, et al. Pharmacological properties of a new selective antigestagen: ORG 3368. Ann NY Acad Sci 1995;761:192-201
5. Donaldson MS, Dorflinger L, Brown SS, Benet LS, editors. Clinical applications of mifespristone RU 486 and other antiprogestins. Washington: National Academy Press; 1993
6. Beier HM, Spitz IM. Progesterone antagonists in reproductive medicine and oncology. Hum Reprod 1994;9(Suppl 1)
7. Agarwal MK. Antihormonal steroids revisited. Drugs Future 1995;20:90310
8. Mahajan DK, London SN. Mifepristone (RU486): a review. Fertil Steril 1997;68:967-76
9. Tang OS, Ho PC. Clinical applications of mifepristone. Gynecol Endocrinol 2006;22:655-9
10. Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Ann Rev Pharmacol Toxicol 1996;36:47-81
11. Blithe DL, Nieman LK, Blye RP, et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 2003;68:1013-7
12. Benagiano G, Primiero FM. Uterine leiomyomata: medical treatment. In: Brosens I, editor, Uterine leiomyomata. London & New York: Taylor & Francis; 2005. p. 237-56
13. Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 2000;65:807-15
14. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003;68:981-93
15. Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator: development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38
16. Benagiano G, Primiero FM. The potential use of antiprogestins in gynaecological disorders. In: Motta M, Serio M, editors, Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects. Amsterdam: Elsevier Science; 1994. p. 391-99
17. Demanno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-32
18. Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008;14:181-91
19. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-36
20. Benagiano G, Bastianelli C, Farris M. Contraception today. Ann NY Acad Sci 2006;1092:1-32
21. Von Hertzen H, Van Look PFA. Antiprogestins for contraception? Semin Reprod Med 2005;23:92-100
22. Herrmann W, Wyss R, Riondel A, et al. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. CR Acad Sci Paris 1982;294:933-8
23. Brown A, Cheng L, Lin SQ, Baird D. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70
24. Croxatto HB, Salvatierra AM, Croxatto HD, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993;8:201-7
25. Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8(6):870-3
26. Ledger WL, Sweeting VM, Hillier H, Baird DT. Inhibition of ovulation by low-dose mifepristone (RU-486). Hum Reprod 1992;7:945-50
27. Marions L, Viski S, Gemzell-Danielsson K, et al. Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum Reprod 1999;14:2788-9
28. Lakha F, Ho PC, Van Der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel) Hum Reprod 2007;22:2428-36
29. Gemzell-Danielsson K, Westlund P, Johannisson E, et al. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1996;11:256-64
30. Marions L, Gemzell-Danielsson K, Swahn ML, Bygdeman M. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998;70:813-6
31. Spitz IM, Croxatto HB, Salvatierra AM, Heikinheimo O. Response to intermittent RU 486 in women. Fertil Steril 1993;59:971-5
32. Kekkonen R, Alfthan H, Hauldcamaa M, et al. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin. Fertil Steril 1990;53:747-50
33. Kekkonen R, Lahteenmaki P, Luukkainen T, Tuominen J. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception. Fertil Steril 1993;60:610-5
34. Kekkonen R, Croxatto HB, Lahteenmaki P, et al. Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation. Hum Reprod 1995;10:287-92
35. Croxatto HB, Massai MR, Salvatierra AM, et al. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. Contraception 1996;54:79-86
36. Sivin I, Nash H, Waldman S. Jaddle® levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience. New York: The Population Council; 2002
37. Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000;15:1969-72
38. Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004;70:47-54
39. Primiero FM, Benagiano G. Long-acting contraceptives. In: Goldzieher JW, Fotherby K, editors, Pharmacology of the contraceptive steroids. New York: Raven Press; 1994. p. 153-83
40. Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003;68:1115-9
41. Li A, Felix JC, Yang W, et al. Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxy-progesterone acetate users. Contraception 2007;76:57-67
42. Li A, Felix Jc, Yang W, Jain JK. Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxy progesterone acetate users. Fertil Steril 2007 Dec 21.
43. Jain JK, Li A, Yang W, et al. Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Fertil Steril 2007;87:8-23
44. Abdel-Aleem H, D'arcangues C, Vogelsong KM, Gülmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007;4:CD003449
45. Sitruk-Ware R. Delivery options for contraceptives. Drug Discov Today 2005;10:977-85
46. Verbost PM, Kloosterboer HJ, Schoonen WGJE, et al. Differential antiprogestin potencies: ORG 31710 versus ORG 33628 for menstrual induction in desogestrel treated monkeys. In: Program and Abstracts of the 80th Annual Meeting; The Endocrine Society; 1998. p. 256
47. Benagiano G, Primiero FM. The new minipill with 75 μg of desogestrel. Ann NY Acad Sci 2003;997:163-73
48. Van Heusden AM, Killick SR, Coelingh-Bennink HJT, Fauser BCJM. Single monthly administration of the antiprogestagen Org 31710 in users of the 75 mg desogestrel progestagen-only pill: effects on pituitary-ovarian activity. Hum Reprod 2000;15:629-36
49. Gemzell-Danielsson K, Van Heusden AM, Killick SR, et al. Improving cyde control in progestin-only contraceptive pill users by intermittent treatment with a new antiprogestin. Hum Reprod 2002;17:2588-93
50. Verbost PM, Hanssen RGJM, Korver GHV, Mulders TMT. ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens. Semin Reprod Med 2005;23:101-11
51. Katkam RR, Gopalkrishnan K, Chwalisz K, et al. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception. Am J Obstet Gynecol 1995;173:779-87
52. Gopalkrishnan K, Katkam RR, Sachdeva G, et al. Effects of an antiprogestin onapristone on the endometrium of bonnet monkeys: morphometric and ultrastructural studies. Biol Reprod 2003;68:1959-67
53. Cameron ST, Critchley HO, Buckley CH, et al. The effects of post-ovulatory administration of onapristone on the developmnent of a secretory endometrium. Hum Reprod 1996;11:40-9
54. Heikinheimo O, Vani S, Carpén O, et al. Intrauterine release of progesterone antagonist ZK23021 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod 2007;22:2515-22
55. World Health Organisation. Emergency contraception WHO/RHR/Fact Sheet 244. Geneva: World Health Organaisation; 2000
56. World Health Organisation. Emergency contraception. A Guide for Service Delivery. Geneva: World Health Organaisation; 1998
57. Bastianelli C, Farris M, Benagiano G. Emergency contraception: a critical review. Eur J Contracept Reprod Health Care 2008;13:9-16
58. Von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet 2000;360:1803-10
59. World Health Organisation. Task Force on Post-ovulatory Methods for Fertility Regulation. 1999. Comparison of three single doses of mifepristone as emergency contraception: a randomized trial. Lancet 1999;353:697-702
60. Von Hertzen H, Van Look PFA. Research on new methods of emergency contraception. Int Fam Plan Perspect 1996;22:62-8
61. Von Hertzen H, Piaggio G. Levonorgestrel and mifepristone in emergency contraception. Steroids 2003;68:1107-13
62. International Medical Advisory Panel. International Planned Parenthood Federation. IMAP statement on emergency contraception. IPPF Med Bull 2004;38:1-3
63. Cheng L, Gülmezoglu AM, Piaggio G, et al. Interventions for emergency contraception. Cochrane Database Syst Rev 2008;2:CD001324
64. Croxatto HB, Fuentealba B, Brache V, et al. Effects of the Yuzpe regimen, given during the follicular phase on ovarian function. Contraception 2002;65:121-8
65. Lalitkumar PG, Lalitkumar S, Meng CX, et al. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum Reprod 2007;22:3031-7
66. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstet Gynecol 2006;107:1089-97
67. Cameron ST, Critchley HO, Buckley CH, et al. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertil Steril 1997;67:1046-53
68. Al-Sunaidi M, Tulani T. Uterine leiomyoma embolization. In: Brosens I, editor, Uterine leiomyomata: pathogenesis and management. London and New York: Taylor & Francis; 2005. p. 237-56
69. Farquhar C, Arroll B, Ekeroma A, et al. An evidence-based guideline for the management of uterine fibroids. Aust N Z J Obstet Gynaecol 1999;41:125-40
70. Agency for Healthcare Research. Management of uterine fibroids. Evidence Report/Technology Assessment 34. Washington:AHRQ. 2001;Publ 01-E051
71. Lefebvre G, Vilos G, Allaire C, Jeffrey J. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003;25:396-405
72. Haney AF. Clinical decision-making regarding leiomyomata: what we need in the next millennium. Environ Health Perspect 2000;108:835-9
73. Floridon C, Lund N, Thomsen SG. Alternative treatment for symptomatic fibroids. Curr Opin Obstet Gynecol 2001;13:491-5
74. Ansari AH, Bekker G, Ansari VM. Today's therapeutic options for uterine leiomyomas. Womens Health Prim Care 2002;5:603-12
75. Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol 2004;16:239-43
76. Chwalisz K, Perez MC, Winkel C. Asoprisnil, a selective progesterone receptor modulator (SPRM), for the management of symptomatic leiomyomata. In: Brosens I, editor, Uterine leiomyomata: pathogenesis and management. London and New York: Taylor & Francis; 2006. p. 301-11
77. Myers ER, Barber MD, Gustilo-Ashby T, et al. Management of uterine leiomyomata: what do we really know? Obstet Gynecol 2002;100:8-17
78. Cai YR, Diao XL, Wang SF, et al. X-chromosomal inactivation analysis of uterine leiomyomas reveals a common clonal origin of different tumor nodules in some multiple leiomyomas. Int J Oncol 2007;31:1379-89
79. Zaloudek C, Norris HJ. In: Kurman RG, editor, Blaunstein's pathology of the female genital tract. 5th edition. New York: Springer-Verlag; 2002. p. 373-408
80. Segaloff A, Weed JC, Sternberg WH, et al. The progesterone therapy of human uterine leiomyomas. Endocrinol Metab 1949;9:1273-91
81. Goldzieher JW, Maqueo M, Ricaud L, et al. Induction of degenerative changes in uterine myomas by high-dosage progestin therapy. Am J Obstet Gynecol 1966;96:1078-87
82. Benagiano G, Morini A, Aleandri V, et al. Sequential Gn-RH superagonist and medroxyprogesterone acetate treatment of uterine leiomyomata. Int J Obstet Gynecol 1990;33:333-43
83. Smith SK. The regulation of fibroid growth: time for a re-think? Br J Obstet Gynaecol 1993;100:977-8
84. Friedman AJ, Barbieri RL, Doubilet PM. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988;49:404-9
85. West CP, Lumsden MA, Hillier H, et al. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum reprod 1992;7:328-32
86. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-23
87. Kawaguchi K, Fujii S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989;160:637-41
88. Sun M, Zhu G, Zhou L. Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata (in Chinese). Zhonghua Fu Chan Ke Za Zhi 1998;33:227-31
89. Yang Y, Zheng S, Zhang Z. Effects of mifepristone on gene expression of epidermal growth factor in human uterine leiomyoma. Zhonghua Fu Chan Ke Za Zhi 1998;33:38-9
90. Alvarez-Murphy A, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-7
91. Yen SSC. Clinical use of RU 486 in the treatment of uterine fibroids. In: Donaldson MS, Dorflinger L, Brown SS, Benet LS, editors, Clinical applications of mifepristone (RU 486) and other antiprogestins. Washington: National Academy Press; 1993. p. 189-209
92. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-6
93. Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size. A randomized controlled trial. Obstet Gynecol 2006;108:1381-7
94. Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol 1994;170:1623-7
95. Morikawa A, Ohara N, Qin X, et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 2008;23:944-51
96. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-36
97. Lessey BA, Metzger DA, Haney AF, McCarty KS Jr. Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril 1989;51:409-15
98. Wolf JP, Hsiu JG, Anderson TL, et al. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 1989;52:1055-60
99. Chwalisz K, Garg R, Brenner RM, et al. Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann NY Acad Sci 2002;955:373-88
100. Kettel LM, Murphy AA, Mortola JF, et al. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 1991;56:402-7
101. Kettel LM, Murphy AA, Morales AJ, et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 1993;60:642-6
102. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8
103. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endomettiosis with low-dose mifepristone (RU486). Am J Obstet Gynecol 1998;178:1151-6
104. Das C, Catt KJ. Antifertility actions of the progesterone antagonist RU 486 include direct inhibition of placental hormone secretion. Lancet 1987;12:599-601
105. Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988;158:5-11
106. Schmidt PJ, Nieman LK, Grover GN, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 1991;324:1174-9
107. Messinis IE, Krishnan M, Kazem R, et al. Effect of mifepristone on folliculogenesis in women treated with recombinant FSH. Clin Endocrinol 1997;46:309-14
108. Available from: www.ClinicalTrials.Gov
109. Escudero EL, Boerrigter PJ, Coelingh-Bennink HJT, et al. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2005;90:2081-8